- Conditions
- KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies, CRC (Colorectal Cancer)
- Interventions
- KQB365, Cetuximab, KQB198
- Drug
- Lead sponsor
- Kumquat Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 206
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, Non Small Cell Lung, Carcinoma, Squamous Cell of Head and Neck, Head and Neck Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Cancer
- Interventions
- PF-08046876, Pembrolizumab, Cisplatin, Carboplatin
- Drug · Combination Product
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 21
- States / cities
- Duarte, California • Irvine, California • Los Angeles, California + 11 more
- Conditions
- Kidney Injury
- Interventions
- Clinical Recommendations
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Type 2 Diabetes
- Interventions
- Decision support, Facilitated referral to a cardiometabolic team-based center
- Other
- Lead sponsor
- American College of Cardiology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2-Positive Breast Carcinoma, Early Stage Triple-Negative Breast Carcinoma
- Interventions
- Biospecimen Collection, Hormone Therapy, Pembrolizumab, Pertuzumab, Trastuzumab
- Procedure · Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronotropic Incompetence
- Interventions
- Blended Sensor Optimization (BSO), Accelerometer Alone (AA)
- Device
- Lead sponsor
- Vivek Reddy
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Heart Failure
- Interventions
- Placebo, Nesiritide, Dopamine
- Other · Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 4 more
- Conditions
- Seizures
- Interventions
- Ezogabine/Retigabine IR, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 9
- States / cities
- Fresno, California • Santa Monica, California • Colorado Springs, Colorado + 6 more
- Conditions
- Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms
- Interventions
- E7386, Lenvatinib, Doxorubicin, Paclitaxel
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 301 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 22 more
- Conditions
- Bipolar Depression
- Interventions
- Medtronic Percept RC System, One Month Blinded Discontinuation Period
- Device · Behavioral
- Lead sponsor
- Wayne Goodman MD
- Other
- Eligibility
- 22 Years to 64 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Houston, Texas • Seattle, Washington
- Conditions
- Atrial Fibrillation (AF), Heart Failure, Catheter Ablation, Guideline Implementation
- Interventions
- LAP-Triggered Heart Failure Optimization Pathway
- Behavioral
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- HIV/AIDS, Nicotine Dependence
- Interventions
- Varenicline, Nicotine patch, Standard treatment, Standard treatment + Managed Problem Solving (MAPS) adherence intervention
- Drug · Behavioral
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Philadelphia, Pennsylvania
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms
- Interventions
- Sofe-M, bevacizumab, carboplatin, Itraconazole, pembrolizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 575 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 11
- States / cities
- Scottsdale, Arizona • La Jolla, California • Atlanta, Georgia + 7 more
- Conditions
- Surgery, Time Restricted Feeding
- Interventions
- Time restricted feeding, Standard dietary advices
- Behavioral
- Lead sponsor
- Centre Hospitalier Universitaire Vaudois
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Participants With Advanced Solid Tumor Malignancies
- Interventions
- VBC106
- Drug
- Lead sponsor
- VelaVigo Bio Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Houston, Texas • West Valley City, Utah • Fairfax, Virginia
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- NHT102, DryNeb
- Drug · Device
- Lead sponsor
- Nob Hill Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Canton, Ohio
- Conditions
- PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
- Interventions
- HWK-016, MUCIN-16-targeted ADC, Bevacizumab
- Drug
- Lead sponsor
- Whitehawk Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Sarasota, Florida + 9 more
- Conditions
- Deprescribing
- Interventions
- Anticipated long-term use of medication, Period re-evaluation of medication
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 2,420 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Pharmacogenetic Testing
- Interventions
- Genecept Assay and G-DIG decision tool
- Genetic
- Lead sponsor
- Seattle Institute for Biomedical and Clinical Research
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Cognitive Dysfunction
- Interventions
- Whole-practice cognitive optimization
- Other
- Lead sponsor
- National University of Natural Medicine
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Encinitas, California
- Conditions
- Advanced Solid Tumor
- Interventions
- BG-C0979, Tislelizumab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • St Louis, Missouri • Hackensack, New Jersey + 1 more
- Conditions
- Epilepsy, Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
- Interventions
- Soticlestat
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 18 more
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck
- Interventions
- 5-Fluorouracil
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC), Papillary Renal Cell Carcinoma (Prcc), Uterine Serous Carcinoma (USC), NSCLC (Non-small Cell Lung Cancer), Primary Peritoneal Cancer
- Interventions
- SIM0505 for injection
- Drug
- Lead sponsor
- NextCure, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 738 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- Orlando, Florida • Atlanta, Georgia • New Orleans, Louisiana + 6 more